Oscient Pharmaceuticals News
Most Popular Oscient Pharmaceuticals Story
ALSO NOTED: Bronchitol gains fast track; Alimera garners $15.9M in second tranche; and much more...
> The FDA has granted fast-track status to Pharmaxis' Bronchitol as a therapy for cystic fibrosis. Investors applauded the news by driving up the value of Pharmaxis' stock about 20 percent on Friday. Pharmaxis has released positive mid-stage data on Bronchitol that demonstrates an improvement in lung function among the patients taking the drug. Pharmaxis plans a complete filing for Bronchitol by 2008. …
... Read more...Latest Headlines
- September 12, 2006
- May 23, 2006
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
